SARS-CoV-2 genomic diversity in households highlights the challenges of sequence-based transmission inference

Authors: Emily Bendall¹, Gabriela Paz-Bailey², Gilberto A. Santiago², Christina A. Porucznik³, Joseph B. Stanford³, Melissa S. Stockwell⁴, Jazmin Duque⁵, Zuha Jeddy⁵, Vic Veguilla², Chelsea Major², Vanessa Rivera-Amill, PhD⁶, Melissa A. Rolfes², Fatimah S. Dawood², Adam S. Lauring^{1,7*}

Affiliations: ¹Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA; ²Centers for Disease Control and Prevention; ³Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine; ⁴Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY; ⁵Abt Associates; ⁶Ponce Health Sciences University/Ponce Research Institute; ⁷Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA;

* **Corresponding Author**: Adam S. Lauring, MS2 4742C, SPC 1621, 1137 Catherine Street, Ann Arbor, MI 48109; (734) 764-7731; <u>alauring@med.umich.edu.</u>

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Keywords: SARS-CoV-2; genomic epidemiology; transmission; household
Running Title: SARS-CoV-2 diversity in households
Abstract Word Count: 200
Main Text Word Count: 3009
Summary: High depth of coverage whole genome sequencing can identify SARS-CoV-2 transmission chains in settings where there is strong epidemiologic linkage but is not reliable as a stand-alone method for transmission inference.

1 ABSTRACT

2	Background: The reliability of sequence-based inference of SARS-CoV-2 transmission is not
3	clear. Sequence data from infections among household members can define the expected
4	genomic diversity of a virus along a defined transmission chain.
5	
6	Methods: SARS-CoV-2 cases were identified prospectively among 2,369 participants in 706
7	households. Specimens with an RT-PCR cycle threshold ≤30 underwent whole genome
8	sequencing. Intrahost single nucleotide variants (iSNV) were identified at \geq 5% frequency.
9	Phylogenetic trees were used to evaluate the relationship of household and community
10	sequences.
11	
12	Results: There were 178 SARS-CoV-2 cases in 706 households. Among 147 specimens
13	sequenced, 106 yielded a whole genome consensus with coverage suitable for identifying iSNV.
14	Twenty-six households had sequences from multiple cases within 14 days. Consensus
15	sequences were indistinguishable among cases in 15 households, while 11 had <a>1 consensus
16	that differed by 1-2 mutations. Sequences from households and the community were often
17	interspersed on phylogenetic trees. Identification of iSNV improved inference in 2 of 15
18	households with indistinguishable consensus sequences and 6 of 11 with distinct ones.
19	
20	Conclusions: In multiple infection households, whole genome consensus sequences differed by
21	0-1 mutations. Identification of shared iSNV occasionally resolved linkage, but the low genomic
22	diversity of SARS-CoV-2 limits the utility of "sequence-only" transmission inference.
23	

24 INTRODUCTION

25	RNA viruses evolve rapidly and accumulate mutations as outbreaks grow [1]. As a result, the
26	evolutionary relationships among sequenced cases hold important information about the
27	processes that drive epidemics [2]. For example, sequence data can help define transmission
28	chains and outbreaks [3–5], the timing and location of viral introductions into communities [6–
29	8], and larger patterns of spread [9–12]. Over the course of the COVID-19 pandemic, SARS-CoV-
30	2 sequences have been used to infer transmission linkage in hospitals and other congregate
31	settings [13–18]. Inferring these linkages with high confidence is necessary for subsequent
32	studies of the biology of transmission and effectiveness of mitigation strategies.
33	
34	To infer transmission, one can ask whether the sequences within a group of close contacts,
35	such as a household, are more similar than sequences in the broader community. This approach
36	depends on both the granularity of the sequence data and the amount of genomic diversity in
37	the underlying community or meta-population. The relatedness of viral sequences identified
38	from potential transmission chains versus community virologic surveillance is compared using
39	phylogenetic trees of whole genome consensus sequences or clustering of transmission-
40	associated sequences [2]. In the setting of insufficient community sampling and/or low genomic
41	diversity, consensus trees can miss true linkages and identify false ones. Greater coverage
42	sequencing can improve resolution by identifying intrahost single nucleotide variants (iSNV) in
43	host-derived viral populations that have yet to achieve consensus levels, or >50% within-host
44	frequency, along a transmission chain [19,20]. While these approaches have proven useful for
45	influenza and other viruses, the reliability of sequence-based inference of SARS-CoV-2

46	transmission is less clear. For example, we and others have found that participants without
47	known epidemiologic linkage can share indistinguishable consensus sequences and even
48	minority (<50%) iSNV [21–23].
49	
50	Households are ideal settings for studies of the biology and epidemiology of viral transmission.
51	Documentation of close contact and concurrent symptoms or test positivity provide strong
52	epidemiologic evidence of within-household transmission. Sequence data from infected
53	participants can therefore define the expected genomic diversity of a virus along a transmission
54	chain and inform sequence-based studies in other transmission settings, where epidemiologic
55	linkage may be uncertain. Here, we use whole genome sequencing of SARS-CoV-2 populations
56	from participants in two prospective household studies of COVID-19 that were conducted at
57	three sites. To assess the utility of SARS-CoV-2 sequence data as a tool for inferring
58	transmission, we used phylogenetic analysis of sequences from households with at least two
59	SARS-CoV-2 infection cases to assess the clustering of within-household sequences relative to
60	contemporaneous community sequences. We used iSNV to further resolve transmission
61	linkages in selected households.
62	
63	METHODS
64	Cohorts
65	The Coronavirus Household Evaluation and Respiratory Testing (C-HEaRT) study enrolled

66 households in Utah (Salt Lake, Weber, Davis, Box Elder, Cache, Tooele, Wasatch, Summit, Utah,

67 and Iron Counties) and New York City [24] during August 2020 through February 2021 and

68 followed them with surveillance for SARS-CoV-2 infection during September 2020 through 69 August 2021. The Communities Organized for the Prevention of Arboviruses (COPA) was 70 expanded to include investigation of the epidemiology of COVID-19, creating the COCOVID study, and recruited households in Ponce, Puerto Rico. For C-HEaRT, household eligibility 71 72 criteria included: ≥1 child aged 0-17 years, ≥75% of household members met individual level 73 eligibility (all members if a 2- or 3-person household), one adult member was willing to 74 complete monthly questionnaires, and adult members could communicate in English or 75 Spanish. Individual eligibility criteria included: anticipated residence in the household for ≥ 3 76 consecutive months, and willingness to complete study surveys, weekly symptom assessments, 77 and self-collect respiratory specimens. For COCOVID, household members were eligible if they were aged ≥ 1 year, slept in the house ≥ 4 nights per week, had no definite plans to move in the 78 79 next year, and were willing and able to comply with study requirements. For both studies, 80 written informed consent (paper or electronic) was obtained from adults (aged >18 years in C-81 HEaRT and >20 years in COCOVID). Parents or legal guardians of minor children provided 82 written informed consent on behalf of their children; older children (aged 12-17 years in C-83 HEaRT and 7–20 years in COCOVID) also provided assent to study participation. The C-HEaRT 84 study protocol was reviewed and approved by the University of Utah Institutional Review Board 85 (IRB) as the single IRB for all collaborators. The COCOVID study protocol was reviewed and 86 approved by the Ponce Medical School Foundation, Inc. IRB.

87

88 Sample Collection and Testing

89 Participants were asked to self-collect (or parent/guardian-collect for children) mid-turbinate 90 nasal swabs every week, regardless of illness symptoms, and place the swabs in viral transport 91 media. Participants were also contacted by text message or email every week to ascertain if 92 they had COVID-19-like (CLI) or any other illness symptoms; they were asked to self-collect an 93 additional mid-turbinate flocked nasal swab once with onset of CLI symptoms. CLI was defined 94 as 1 or more of the following: fever or feverishness, cough, shortness of breath, sore throat, 95 diarrhea, muscle aches, chills, or change in taste or smell. Respiratory specimens were shipped 96 overnight to a central lab and tested using either the Quidel Lyra SARS-CoV-2 Assay or the 97 ThermoFisher Combo Kit platform. The assays were approved under Emergency Use 98 Authorization for the diagnosis of SARS-CoV-2 infection prior to use in this study. Test-positive infections in the same household that were first detected by RT-PCR within 14 days of each 99 100 other (including those detected on the same date) were considered epidemiologically linked 101 and likely to have resulted from within-household transmission. 102 SARS-CoV-2 Genomic Sequencing 103 104 SARS-CoV-2 genomic sequencing was attempted on all specimens with an RT-PCR cycle 105 threshold (Ct) \leq 30 on either the nucleocapsid protein 1 or 2 target. SARS-CoV-2 genomes were 106 sequenced as described previously [10]. Briefly, RNA was extracted from midturbinate nasal 107 swab specimens with the MagMax MVPII viral nucleic acid isolation kit on a Kingfisher Flex 108 (Thermofisher) and reverse transcribed with Lunascript (NEB). We amplified SARS-CoV-2 cDNA 109 in two pools using the ARTIC Network v3 primers and protocol. Amplicon pools were combined 110 in equal volumes for a given sample and purified with magnetic beads. Barcoded sequencing

libraries were prepared using the NEBNext ARTIC SARS-CoV-2 Library Prep Kit with magnetic
bead size selection. Individual barcoded sample libraries were pooled (up to 96) and sequenced
on an Illumina MiSeq (v2 chemistry, 2x250 cycles).

114

115	Reads were mapped to the Wuhan/Hu-1/2019 reference genome (GenBank MN908947.3) with
116	BWA-MEM [25]. We used iVar 1.2.1 [26] to trim ARTIC amplification primer sequences and to
117	determine consensus sequences using bases with >50% frequency and placing a designated
118	unknown base N at positions covered by fewer than 10 reads. Genomes with 29,000 or more
119	unambiguous bases (> 97% completeness) were used in downstream analysis. We identified
120	iSNV with iVar using the following parameters: sample with a minimum consensus genome
121	length of 29,000 bases; sample with an average genome sequencing coverage depth of greater
122	than 200 reads per position; iSNV frequency of 5–95%; read depth of 400 at iSNV sites with a
123	Phred score of >30; iVar p-value of <0.00001. We masked sites commonly affected by
124	sequencing errors in both consensus sequences and iSNV calls [27].

125

126 Phylogenetic Analysis

127 Consensus sequences for each household were placed on the global SARS-CoV-2 phylogenetic 128 tree using UShER [28]. The tree versions used were from the week of 14 February 2022 and 129 included over 7.8 million genome sequences from GISAID, GenBank, COG-UK and CNCB. The 130 level of genomic sampling of the state or territory of each study site (Figure 1) was estimated 131 with subsampler [10] using case data and GISAID submission data. Subtrees were initially 132 constructed with 30 samples and then reconstructed with additional samples as needed to

133	visualize all genomes from a household in a single subtree (e.g., when samples existed within
134	large clusters of indistinguishable samples). The JSON files for each master tree and subtree are
135	available in Supplemental Dataset 1 and can be visualized in the auspice viewer at
136	https://auspice.us/. Trees were annotated and edited in FigTree using the subtree.nwk files
137	generated by UShER.
138	
139	Data and materials availability
140	The consensus genomes that we generated for this study are publicly available on
141	https://github.com/lauringlab/SARS-CoV-2_Household_Diversity Accessions. Those for the
142	community sequences (largely from GISAID) can be found in the pdf tree files
143	(" <household_id>.pdf") in Supplemental Dataset 1. Laboratories responsible for submissions</household_id>
144	are acknowledged in Supplemental Table 1. Analysis code for the generation of consensus
145	sequences and phylogenetic analysis are available at https://github.com/lauringlab/SARS-CoV-
146	2 Household Diversity.
147	
148	RESULTS
149	The C-HEaRT (Utah and New York City) and COCOVID (Puerto Rico) studies performed active
150	surveillance for SARS-CoV-2 infection and CLI in 706 households with 2,369 participants (Table
151	1). During September 2020 through August 2021, the cumulative incidence of SARS-CoV-2
152	infection was 11% [96/842 participants in 41/190 (22%) households under surveillance] at the

153 Utah site and 7% [33/499 participants in 13/135 (10%) households] at the New York City site;

during June 2020 through September 2021, cumulative incidence was 5% at the Puerto Rico site
(49/1028 infections detected in 28/381 households).

156

157	Of the 191 participants with SARS-CoV-2 infections in these households, 147 (77%) in 70
158	households had samples with a Ct value <30 that were processed for whole genome
159	sequencing, of whom, 106 (72%) had samples that were successfully sequenced to sufficient
160	breadth and depth of coverage (see Methods). Of the 706 households at the three sites, 56
161	included ≥2 participants who were test-positive within a 14-day period, suggestive of within-
162	household transmission (Table 1). Twenty-six households had high quality sequence data on ≥ 2
163	of these contemporaneous infections. The SARS-CoV-2 clades and lineages identified (Table 2)
164	were the same among participants of the same household and reflect viruses circulating in the
165	corresponding time periods in the United States (www.outbreak.info)(Table 2).
166	
167	We first used phylogenetic analysis of whole genome sequences to infer transmission linkage
168	within these 26 households. We used Usher [28] to obtain local sequences for each household
169	and to place household sequences simultaneously on a phylogenetic tree. Over 7.8 million
170	whole genome SARS-CoV-2 sequences were available at the time of this analysis. Because most
171	of these contextual sequences were from GISAID, we estimated the level of sampling at each
172	study site over time by dividing the number of GISAID sequences by the number of reported
173	cases [10]. Sampling of locally circulating viruses was low in 2020 (<2% cases sequenced) and
174	increased at all three sites beginning in early 2021 (>5% cases sequenced, Figure 1). In 2022,
175	Utah was generally better sampled (~10-30%) than New York or Puerto Rico (5-15%).

176

177	In 15 out of the 26 households that we studied, the consensus sequences of all cases were
178	indistinguishable and grouped together on their respective trees (representative trees in Figure
179	2, additional trees in Supplemental Figures 1-4). Given the epidemiologic linkage in the same
180	household, these can be considered sequence-confirmed transmission events. However, we
181	also found several trees in which these monophyletic groupings also included indistinguishable,
182	contemporaneous sequences from non-household members within the community of the same
183	locality (see trees in Figure 2). In two of the New York households, there were many such
184	sequences during a B.1.526 (lota) variant wave (Supplemental Figures 1 and 2). Therefore, even
185	with a modest level of sampling (Figure 1), it is not uncommon to find indistinguishable viral
186	sequences from participants at the same region and time who presumably lack a documented
187	epidemiologic linkage.

188

189 In 11 households, the consensus sequences of the virus from one or more household members 190 differed at 1-2 positions over the nearly 30kb genome. This is not uncommon in transmission 191 chains, particularly ones that are longer or in which the samples are collected 7-14 days apart 192 (see Table 2 for time span). In nearly all cases, the trees from these households demonstrated 193 linkage and/or an ancestor/descendant relationship for the viral sequences (representative 194 trees in Figure 3, additional trees in Supplemental Figure 5). In some cases, the household lineages were phylogenetically distinct from contemporaneous local sequences (e.g., UT2, UT4). 195 196 These tree structures supported transmission linkage, but low sampling of community cases 197 makes it hard to rule out missed linkages between members of the household and the larger

community. Indeed, there were some households in which there were sequences from the
larger community included among the same branches of the within-household sequences (e.g.,
UT10, PR3). As above, the low genomic diversity of SARS-CoV-2 and modest sampling of
community cases made it difficult to define a threshold to effectively rule in or rule out
transmission.

203

204 We next determined whether transmission inference could be improved by identifying iSNV 205 that were shared among members of a household. These would manifest as polymorphic sites 206 where the alternative allele, or mutation, is present but not fixed in the transmission chain. 207 While there was just one household where two participants shared a minority iSNV (PR5, Figure 208 4), several had iSNV in at least one individual at a consensus level (i.e., frequency >0.5), but that 209 had not yet achieved fixation (i.e., frequency >0.95). In the 15 households with 210 indistinguishable consensus sequences, each of the two participants in households NY5 and PR5 211 shared an iSNV that was consensus level, but not fixed. In three (UT12, UT5, UT3) out of the 11 212 households with distinct consensus sequences (Table 2), the consensus differences were due to 213 one or more participants having a non-reference iSNV that achieved consensus level, but not 214 fixation. Household UT4 had two participants with consensus level iSNV (Figure 4). In household PR3, there was one site where one out of four members had a consensus level iSNV and 215 216 another member had this as a fixed mutation.

217

218 **DISCUSSION**

219	We evaluated the utility of SARS-CoV-2 sequence data in transmission inference using data
220	from two studies of household cohorts at three sites. In the household setting, where at least
221	two incident infections occurring within 14 days of one another are strongly suggestive of
222	transmission, we found that sequencing generally confirmed transmission linkage. The whole
223	genome consensus sequences of participants within a household were nearly always
224	indistinguishable or differed by one mutation. In some cases, these links were further
225	supported by the identification of iSNV shared among members of the household. Out of the 26
226	households evaluated, there was just one (UT10) in which the high average number of
227	consensus differences (two) and absence of shared iSNV called linkage into doubt. Importantly,
228	we frequently found multiple sequences from the community that were indistinguishable to
229	those within the household with even modest sampling (<5%) over the course of the pandemic.
230	This highlights the limits of "sequence-only" inference of transmission in hospitals or other
231	congregate settings where epidemiologic linkage is less certain.
232	
233	Strengths of the study include our reliance on samples from active surveillance of longitudinal
234	cohorts and our use of quality controlled, deep sequencing. With weekly sampling of all
235	participants from a household, we were able to identify asymptomatic or mildly symptomatic
236	cases and avoid some of the bias of case-ascertainment studies, in which cases are recruited
237	based on a test-positive index. Together with our use of contemporaneous community
238	specimens collected from participants not in the households but from the same site, our data
239	provide a valuable benchmark for the expected SARS-CoV-2 diversity in households relative to
240	that in the community. The cohorts are also drawn from diverse geographic areas with varied

241	household sizes and composition [21,29]. Our assessment of viral diversity is strengthened by
242	our criteria for identifying consensus and minority iSNV [22]. The low observed diversity in this
243	study, in part, reflects the stringent thresholds applied to the sequence data . This conservative
244	approach reduces sequencing errors, which can be systematic and lead to incorrect
245	ascertainment of shared iSNV among unrelated participants [21–23,30].
246	
247	This study had several notable limitations. First, we were relatively stringent in our criteria for
248	identifying iSNV and therefore may have underascertained shared diversity in the rare (<5%)
249	variant fraction within households. Second, given the limited number of households with
250	sequenced cases, we were unable to formulate a statistically robust approach to sequence-
251	based inference with clear cut-offs and associated positive and negative predictive values. Case-
252	ascertained cohorts or contact tracing studies offer a more efficient way to capture and
253	sequence many putative transmission pairs and will be useful as a setting in which to further
254	develop this approach. Third, while we believe that our data provide an important framework
255	for interpreting sequence data in studies of SARS-CoV-2 transmission, data from households
256	may not translate completely to hospitals and other congregate living settings, which may differ
257	in case density, contact frequency, and force of infection. Fourth, we assumed that household
258	cases testing positive for SARS-CoV-2 within 14 days of one another were linked by
259	transmission. If these cases represented distinct introductions into the household, we could
260	overestimate expected within-household diversity. Fifth, it is possible, but in our opinion

261 unlikely, that some of the community cases in our analysis actually had an epidemiologic

262 linkage to participants in these households.

263

264	Despite the limitations identified in this study, integration of sequence and epidemiologic data
265	can be a powerful approach to studies of SARS-CoV-2 transmission. In settings where there is
266	strong epidemiologic linkage among cases (e.g., known exposure or clear temporal and spatial
267	association), indistinguishable consensus sequences with or without shared iSNV should be
268	confirmatory. In these situations, single mutation differences among consensus sequences in a
269	cluster are not uncommon; mutations can fix along a transmission chain, particularly longer
270	ones over a greater timespan. However, if epidemiologic linkage is less certain, sequence
271	identity can only confirm transmission if the metapopulation is highly sampled and genetically
272	diverse. For example, early in the pandemic when circulating SARS-CoV-2 diversity was low,
273	many inpatients and employees in hospitals were found to share indistinguishable consensus
274	sequences, and even iSNV, without any apparent epidemiologic linkage [22,31]. This contrasts
275	with other studies of hospital outbreaks where the combination of contact tracing and
276	sequence data confirmed suspected transmission chains and identified new ones. We expect
277	that future studies of transmission in households, hospitals, and other congregate settings will
278	benefit from Bayesian methods, which can integrate epidemiologic and sequence data for
279	improved inference [32].
280	

281 ACKNOWLEDGMENTS

We thank the participants in the C-HEaRT and COCOVID cohorts and all GISAID submitting
laboratories. We acknowledge Anderson Britto for developing and suggesting the subsampler
tool used to generate Figure 1.

285 **REFERENCES**

- Lauring AS. Within-Host Viral Diversity: A Window into Viral Evolution. Annu Rev Virol
 2020; 7:63–81.
- 288 2. Kao RR, Haydon DT, Lycett SJ, Murcia PR. Supersize me: how whole-genome sequencing
- and big data are transforming epidemiology. Trends Microbiol **2014**; 22:282–291.
- 290 3. Lemieux JE, Siddle KJ, Shaw BM, et al. Phylogenetic analysis of SARS-CoV-2 in Boston
- highlights the impact of superspreading events. Science **2021**; 371:eabe3261.
- 4. Siddle KJ, Krasilnikova LA, Moreno GK, et al. Transmission from vaccinated individuals in a

large SARS-CoV-2 Delta variant outbreak. Cell **2022**; 185:485-492.e10.

- 294 5. Zeller M, Gangavarapu K, Anderson C, et al. Emergence of an early SARS-CoV-2 epidemic in
- the United States. Cell **2021**; 184:4939-4952.e15.
- Worobey M, Pekar J, Larsen BB, et al. The emergence of SARS-CoV-2 in Europe and North
 America. Science **2020**; 370:564–570.
- 298 7. du Plessis L, McCrone JT, Zarebski AE, et al. Establishment and lineage dynamics of the
 299 SARS-CoV-2 epidemic in the UK. Science **2021**; 371:708–712.
- Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in
 Brazil. Science **2020**; 369:1255–1260.
- Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron
 variant in southern Africa. Nature **2022**; 603:679–686.

204	10	Almort T Drite AF	Lacale Naccalquist F	at al Farb	introductions and	+ransmission	ofCADC
304	TO.	Alpert I, Brito AF	Lasek-inesseiguist E	, et al. Early	v introductions and	i transmission	UI SARS-

- 305 CoV-2 variant B.1.1.7 in the United States. Cell **2021**; 184:2595-2604.e13.
- 306 11. Valesano AL, Fitzsimmons WJ, Blair CN, et al. SARS-CoV-2 Genomic Surveillance Reveals
- 307 Little Spread From a Large University Campus to the Surrounding Community. Open Forum
- 308 Infect Dis **2021**; 8:ofab518.
- 309 12. Aggarwal D, Warne B, Jahun AS, et al. Genomic epidemiology of SARS-CoV-2 in a UK
- 310 university identifies dynamics of transmission. Nat Commun **2022**; 13:751.
- 13. Lucey M, Macori G, Mullane N, et al. Whole-genome Sequencing to Track Severe Acute
- 312 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in Nosocomial Outbreaks.
- 313 Clin Infect Dis **2021**; 72:e727–e735.
- 14. Francis RV, Billam H, Clarke M, et al. The Impact of Real-Time Whole-Genome Sequencing
- in Controlling Healthcare-Associated SARS-CoV-2 Outbreaks. J Infect Dis **2022**; 225:10–18.
- 316 15. Meredith LW, Hamilton WL, Warne B, et al. Rapid implementation of SARS-CoV-2
- 317 sequencing to investigate cases of health-care associated COVID-19: a prospective
- 318 genomic surveillance study. Lancet Infect Dis **2020**; 20:1263–1271.
- 319 16. Hamilton WL, Fieldman T, Jahun A, et al. Applying prospective genomic surveillance to
- 320 support investigation of hospital-onset COVID-19. Lancet Infect Dis **2021**; 21:916–917.
- 321 17. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
- 322 Transmission in a Skilled Nursing Facility. N Engl J Med **2020**; 382:2081–2090.

525 $10.$ Added $7,$ erawiora kind, bingens 7, et al. Neatraining Antiboares correlate with	323	18.	Addetia A	, Crawford KHD	, Dingens A	, et al.	Neutralizing	Antibodies	Correlate with
---	-----	-----	-----------	----------------	-------------	----------	--------------	------------	----------------

- 324 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High
- 325 Attack Rate. J Clin Microbiol **2020**; 58:e02107-20.
- 326 19. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Lauring AS. Stochastic processes
- 327 constrain the within and between host evolution of influenza virus. eLife **2018**; 7:e35962.
- 328 20. Worby CJ, Lipsitch M, Hanage WP. Shared Genomic Variants: Identification of Transmission
- Routes Using Pathogen Deep-Sequence Data. Am J Epidemiol **2017**; 186:1209–1216.
- 330 21. Braun KM, Moreno GK, Wagner C, et al. Acute SARS-CoV-2 infections harbor limited
- within-host diversity and transmit via tight transmission bottlenecks. PLOS Pathog 2021;
 17:e1009849.
- 22. Valesano AL, Rumfelt KE, Dimcheff DE, et al. Temporal dynamics of SARS-CoV-2 mutation
- accumulation within and across infected hosts. PLOS Pathog **2021**; 17:e1009499.
- 335 23. Tonkin-Hill G, Martincorena I, Amato R, et al. Patterns of within-host genetic diversity in
 336 SARS-CoV-2. eLife **2021**; 10:e66857.
- 24. Dawood FS, Porucznik CA, Veguilla V, et al. Incidence Rates, Household Infection Risk, and
- 338 Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and
- 339 New York City, New York. JAMA Pediatr **2022**; 176:59.

340	25.	Li H. Aligning sequence	reads. clone sequence	s and assembly conti	gs with BWA-MEN
340	ZJ .	LI II. Alighting Juquuluu	reads, cione sequence	.5 and assembly contig	

- 341 ArXiv13033997 Q-Bio **2013**; Available at: http://arxiv.org/abs/1303.3997. Accessed 31 July
- 342 2020.
- 343 26. Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing framework
- for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol
 2019; 20:8.
- 346 27. De Maio N, Walker C, Borges R, Weilguny L, Slodkowicz G, Goldman N. Masking strategies
- 347 for SARS-CoV-2 alignments. Virological. 2020; Available at:
- 348 https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480. Accessed 10
 349 March 2022.
- 28. Turakhia Y, Thornlow B, Hinrichs AS, et al. Ultrafast Sample placement on Existing tRees
- 351 (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. Nat Genet 2021;
 352 53:809–816.
- Walter KS, Kim E, Verma R, et al. Shared within-host SARS-CoV-2 variation in households.
 medRxiv **2022**; :2022.05.26.22275279.
- 30. Lythgoe KA, Hall M, Ferretti L, et al. SARS-CoV-2 within-host diversity and transmission.
 Science 2021; :eabg0821.
- 357 31. Braun KM, Moreno GK, Buys A, et al. Viral Sequencing to Investigate Sources of SARS-CoV-
- 2 Infection in US Healthcare Personnel. Clin Infect Dis **2021**; 73:e1329–e1336.

- 359 32. Lindsey BB, Villabona-Arenas ChJ, Campbell F, et al. Characterising within-hospital SARS-
- 360 CoV-2 transmission events using epidemiological and viral genomic data across two
- 361 pandemic waves. Nat Commun **2022**; 13:671.

362

364 **Table 1:** Distribution of SARS-CoV-2 test-positive cases across cohorts and households

365

	New York		Puerto
	City	Utah	Rico
Number of Households	135	190	381
Number of Participants	499	842	1028
Median household size (range)	4 (2-9)	4 (2-10)	2 (1-6)
Number of unique SARS-CoV-2-positive			
Cases ^a	33	96	49
Households with 1 case	3	17	3
Households with 2 cases ^b	5	7	5
Households with 3 cases ^b	3	5	8
Households with 4 cases ^b	0	4	6
Households with 5 cases ^b	1	4	5
Households with 6 cases ^b	1	0	1
Households with 7 cases ^b	0	1	0
# of cases with sequence data / #			
sequenced	28/29	52/86	26/32

^a total number over study period

^b only households with cases testing positive within 14 days of each other

367	Table 2: Households with two or more incident SARS-CoV-2 infections within a 14- day period
368	

Household	Number of	Date First	Date Last	Nextclade	PANGO	Mean
	Specimens Sequenced	Specimen	Specimen	Clade ^a	lineage ^b	Consensus Diff ^c
PR1	3	9/2/20	9/8/20	20C	B.1.426	0
UT1	3	10/14/20	10/15/20	20G	B.1.2	0
PR2	4	10/24/20	10/30/20	20C	B.1.588	0.5
UT2	4	11/17/20	11/24/20	20B	B.1.1	0.5
UT3	6	11/24/20	12/2/20	20G	B.1.2	1.4
UT4	4	11/30/20	12/7/20	20B	B.1.1	1.5
UT5	2	12/2/20	12/3/20	20A	B.1.400	1
UT6	3	12/3/20	12/10/20	20G	B.1.2	0.67
PR3	4	12/3/20	12/11/20	20B	B.1.1.486	1.17
UT7	3	12/15/20	12/28/20	20A	B.1.596	0
UT8	2	12/28/20	1/1/21	21C (Epsilon)	B.1.429	0
UT9	2	1/12/21	1/14/21	20A	B.1.400	0
NY1	3	1/29/21	2/4/21	21F (iota)	B.1.526	0.67
PR4	2	2/8/21	2/8/21	20A	B.1.240	0
NY2	3	2/9/21	2/9/21	21F (lota)	B.1.526	0
NY3	3	2/11/21	2/18/21	20C	B.1.582	0
NY4	2	2/21/21	3/5/21	21F (iota)	B.1.526	0
NY5	2	2/23/21	2/23/21	21F (lota)	B.1.526	0
NY6	6	2/24/21	3/11/21	20C	B.1.637	1.13
UT10	2	3/1/21	3/15/21	21C (Epsilon)	B.1.427	2
NY7	3	3/3/21	3/16/21	20C	B.1.637	0
NY8	2	3/22/21	4/4/21	21F (lota)	B.1.526	0
PR5	2	3/23/21	3/30/21	20B	R.1	0
PR6	3	4/23/21	4/23/21	20I (Alpha,V1)	Q.4	0
UT11	3	7/26/21	8/10/21	21J (Delta)	AY.44	0
UT12	2	8/4/21	8/4/21	21J (Delta)	AY.44	1

a Defined using nextclade, https://clades.nextstrain.org

b Defined using pango, https://cov-lineages.org/resources/pangolin.html

c Total number of pairwise unambiguous consensus differences between sequences divided by total number of sequences in a household

371 FIGURE LEGENDS

372

373	Fig. 1: Cases and sampling density. Columns show the number of SARS-CoV-2 infections (left y-
374	axis) in households from New York (NY, top), Puerto Rico (PR, middle), and Utah (UT, bottom)
375	cohorts by epiweek (x-axis). The sampling density (line) for community genomes in each state
376	or territory (right y-axis) was estimated as the proportion of cases with sequences available on
377	GISAID.
378	
379	Fig. 2: Phylogenetic trees of sequences from households where all participants had
380	indistinguishable consensus sequences. Shown are four representative trees. Trees from 11
381	other households are shown in Supplemental Figures 1-4. Each tree is labeled with the
382	household identifier (NY = New York, UT = Utah, PR = Puerto Rico). The tips of household
383	sequences are colored cyan and those from non-household participants in the same community
384	in the same state or territory (2 letter abbreviation) are colored magenta. All other tips are
385	colored black. The collection date for each specimen is indicated. Genetic distance is
386	represented by the bar and corresponds to one mutation.
387	
388	Fig. 3: Phylogenetic trees of sequences from households where participants had distinct
389	consensus sequences. Shown are four representative trees. Trees from 7 other households are
390	shown in Supplemental Figure 5. Each tree is labeled with the household identifier (NY = New
391	York, UT = Utah, PR = Puerto Rico). The tips of household sequences are colored cyan and those
392	from the same state or territory (2 letter abbreviation) are colored magenta. All other tips are

colored black. The collection date for each sample is indicated. Genetic distance is representedby the bar and corresponds to one mutation.

395

396 Fig. 4: Shared single nucleotide polymorphisms within households. Each panel shows one of 397 the 8 households in which members shared a polymorphic site. The frequency (5-95%) of the 398 indicated mutation (relative to the Wuhan/Hu-1 reference) is shown on the y-axis and the 399 individual/sequence identifier is shown on the x-axis. Shared variants that did and did not lead 400 to a consensus level difference between household members are shown as circles and 401 diamonds, respectively. Mutations that are fixed (>95% frequency) are shown as squares. 402 Supplemental Figures 1-4: Phylogenetic trees of sequences from households where all 403 404 participants had indistinguishable consensus sequences. Each tree is labeled with the 405 household identifier (NY = New York, UT = Utah, PR = Puerto Rico). The tips of household 406 sequences are colored cyan and those from the same state or territory (2 letter abbreviation) 407 are colored magenta. All other tips are colored black. The collection date for each sample is 408 indicated. Genetic distance is represented by the bar and corresponds to one mutation. 409 410 Supplemental Figure 5: Phylogenetic trees of sequences from seven households where 411 participants had distinct consensus sequences. Each tree is labeled with the household 412 identifier (NY = New York, UT = Utah, PR = Puerto Rico). The tips of household sequences are 413 colored cyan and those from the same state or territory (2 letter abbreviation) are colored

- 414 magenta. All other tips are colored black. The collection date for each sample is indicated.
- 415 Genetic distance is represented by the bar and corresponds to one mutation.

416

- 417 Supplemental Table 1: Submitting laboratories for GISAID sequences used in this study. GISAID
- 418 identifiers can be found in the unedited trees in the Supplemental Dataset.





Figure 2



Figure 3



Figure 4



Supplemental Figure 1



Supplemental Figure 2

NY2



Supplemental Figure 3



Supplemental Figure 4



Supplemental Figure 5







0.6



PR2

